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Introduction: Sepsis is still a leading cause of morbidity and mortality, even in modern times, and thrombocytopenia
has been closely associated with unfavorable disease outcome. Decreases in mitochondrial membrane potential
(depolarization) were found in different tissues during sepsis. Previous work suggests that mitochondrial dysfunction of
platelets correlates with clinical disease activity in sepsis. However, platelet mitochondrial membrane potential (Mmp)
has not been investigated in a clinical follow-up design and not with regard to disease outcome.
Methods: In this study, platelet mitochondrial membrane depolarization was assessed by means of a fluorescent
Mmp-Index with flow cytometry in 26 patients with sepsis compared with control patients. Platelet Mmp-Index
on admission was correlated with the clinical disease scores Acute Physiology and Chronic Health Evaluation
Score II (APACHE II), Sequential Organ Failure Score (SOFA), and Simplified Acute Physiology Score II (SAPS II).
Finally, platelet Mmp-Index on admission and follow-up were compared in the group of sepsis survivors and
nonsurvivors. Expression of the prosurvival protein Bcl-xL in platelets was quantified by immunoblotting.
Results: Platelet mitochondrial membrane depolarization correlated significantly with the simultaneously
assessed clinical disease severity by APACHE II (r = −0.867; P < 0.0001), SOFA (r = −0.857; P <0.0001), and SAPS II
score (r = −0.839; P < 0.0001). Patients with severe sepsis showed a significant reduction in platelet Mmp-Index
compared with sepsis without organ failure (0.18 (0.12 to 0.25) versus 0.79 (0.49 to 0.85), P < 0.0006) or with the
control group (0.18 (0.12 to 0.25) versus 0.89 (0.68 to 1.00), P < 0.0001). Platelet Mmp-Index remained persistently
low in sepsis nonsurvivors (0.269 (0.230 to 0.305)), whereas we observed recovery of platelet Mmp-Index in the
survivor group (0.9 (0.713 to 1.017)). Furthermore, the level of prosurvival protein Bcl-xL decreased in platelets
during severe sepsis.
Conclusion: In this study, we demonstrated that mitochondrial membrane depolarization in platelets correlates
with clinical disease severity in patients with sepsis during the disease course and may be a valuable adjunct
parameter to aid in the assessment of disease severity, risk stratification, and clinical outcome.Introduction
Sepsis is still a leading cause of morbidity and mortality
worldwide, despite modern intensive care medicine. Nu-
merous biomarkers have been investigated in the diagnosis
and clinical assessment of sepsis, but only few have found
their way into clinical routine [1]. Although good clinical
scores for disease severity have been developed [2-4],* Correspondence: Bjoern.Kraemer@med.uni-muenchen.de
5Medizinische Klinik und Poliklinik I, Klinikum der Universität München,
Ziemssenstr. 1, 80336 München, Germany
Full list of author information is available at the end of the article
© 2014 Gründler et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orpatient assessment on a daily basis remains a challenge
and could be facilitated by molecular disease parameters.
Evidence is growing that platelets play an active role in
fighting infections and in innate immunity [5-8], and
thrombocytopenia is frequently observed in systemic
infections. Previous studies have found that the severity
of thrombocytopenia is associated with increased mor-
tality rates for patients in intensive care units in general
[9-13]. Although this has been frequently interpreted
as a consumption of platelets [14], signs of cell death
have also been observed in platelets. Just lately, oural Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the apoptotic pathway in platelets to induce platelet cell
death in vitro [15]. Several other groups demonstrated that
the septic milieu compromises mitochondrial function,
which leads to dysfunction of blood cells, myocardium,
and muscle wasting [16-20]. In this context, platelet
mitochondrial function was also affected in the sepsis
patient, and mitochondrial dysfunction correlated with
disease severity and poor outcome in different study
designs [21-24]. The focus of this work was to investi-
gate platelet mitochondrial membrane potential (Mmp)
with flow cytometry with regard to disease outcome
and disease severity in patients with sepsis. Platelet
Mmp was correlated with clinical disease-severity scores
(APACHE II, SOFA, and SAPS II score) on admission and
was compared with that in control patients. We reassessed
platelet Mmp in patients with severe sepsis during the
disease course and compared it in survivors and non-
survivors. The protein Bcl-xL, which regulates apop-
tosis in platelets and is critical for cell survival [25,26],
was investigated in severe sepsis with immunoblotting.
Overall, in this study, we aimed to investigate whether
platelet mitochondrial membrane depolarization could be
a potential biomarker of platelets in sepsis. Our hypothesis
was that mitochondrial membrane depolarization of plate-




Patients with the diagnosis of sepsis or severe sepsis [26],
including septic shock as previously defined [27,28] were
included in the study between January 2012 and January
2013. Clinical disease severity was assessed with APACHE
II, SOFA, and SAPS II scores on the days of blood draws.
Severe sepsis was defined as sepsis complicated by organ
failure [28]. We considered organ failure as a SOFA point
score above 2, as previously used by others [29-31]. Subse-
quently, the patient collective comprised nine patients
with sepsis (nonsevere) and 17 patients with severe sepsis,
including septic shock. Patients were recruited from the
medical intensive care unit, intermediate care unit, and
emergency department of the University Medical Center
Innenstadt of the University Hospital Munich. All patients
were older than 18 years, and written informed consent
was obtained from patients or next of kin. Blood was
drawn within the first 48 hours of admission in all patients
diagnosed with sepsis and in controls.
In the group of patients with severe sepsis, follow-up
blood draws and Mmp reads were taken according to
the clinical follow-up assessment of the patient by the
critical care team, which was based on organ-failure score
SOFA. Follow-up blood draws were initiated if the patient
recovered to a SOFA score of less than 3 points or didnot show improvement from initial SOFA score after
2 weeks (see Additional file 1). An earlier follow-up blood
draw was initiated if the patient showed a rapid clinical
deterioration. On average, follow-up reads were taken
7 days after admission. Seventeen control patients with
noninfectious medical conditions (including gastrointes-
tinal (GI) bleeding, myocardial infarction, pulmonary
embolism, hypertensive urgency, ketoacidosis, arrhythmia,
or COPD) were included after written, informed consent
(Table 1). Control patients had to have at least two per-
manent medical conditions requiring medical therapy
and were matched by age to the severe-sepsis cohort.
For reference, Mmp readings were also taken from
healthy volunteers recruited from our staff. Patients
with known preexisting or chronic thrombocytopenia
or mitochondrial disease, as well as patients with SIRS
unrelated to an infectious cause, were excluded from
the study. The study was approved by the local ethics
committee of the University of Munich in accordance
with the Declaration of Helsinki.
Platelet mitochondrial membrane potential by
flow cytometry
Platelets were isolated from whole blood of patients with
sepsis and controls, as previously described [15], and
mitochondrial membrane potential (Mmp) was measured
with JC-1 dye with flow cytometry, according to the man-
ufacturer’s instructions (Immunochemistry Technologies,
Bloomington, MN, USA). Then 3 × 107 washed platelets
per ml were stained with JC-1 dye for 20 minutes under
cell-culture conditions in the dark. Purification and re-
suspension of platelets in equal volumes and at equal
concentrations guaranteed identical staining and pro-
cessing conditions and equalized the initial differences
in platelet number among the clinical samples. Samples
from patients with thrombocytopenia were thus fully
comparable to samples with normal platelet numbers.
Flow cytometry was performed by using a BD FACS-
CANTO II flow cytometer (BD Biosciences, Heidelberg,
Germany). Mitochondrial membrane potential (Mmp)
was assessed as a ratio of the mean FL2 (red fluorescence)
and FL1 (green fluorescence), as in previous publications
[32]. We called this ratio “Mmp-Index” in the text. A
decrease in the FL2-to-FL1 ratio (Mmp-Index) represents
a loss in mitochondrial membrane potential (depolar-
ization) (see Additional file 2). Mmp-Index was calculated
as the mean of triplicate readings for each patient (see
Additional file 1). Stimulation with calcium ionophore
A23187 (Calbiochem, Darmstadt, Germany) at 10 μM for
10 minutes, which induces platelet apoptosis and rapid
mitochondrial membrane depolarization [33], was used as
an internal positive control to assure correct function of
the assay in each experiment.
Table 1 Clinical patient characteristics
Sepsis Severe sepsis/septic shock Controls
Number of patients 9 17 17
Male/female 6/3 9/8 10/7
Age 57 (42 to 71) 69 (55 to 78) 74 (68 to 79)
Platelet counts (×103/μl) 198 (161 to 210) 98 (79 to 159) 176 (145 to 230)
APACHE II score 9 (8 to 13) 23 (15 to 26)
SOFA score 0 (0 to 1) 7 (5 to 11)
SAPS II score 33 (25 to 35) 53 (40 to 58)
Site of infection Admission cause and number of patients
Pulmonary 4 7 Cardiac 3
Urinary 0 2 Pulmonary 2
Abdominal 3 5 Endocrine 3
Endocarditis 0 1 Rheumatic 1
Soft tissue 0 1 GI 4
Others 2 1 Other 4
Numbers are given as median and (interquartile range).
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Immunoblotting was performed as previously described
[15]. In brief, 1 × 108 platelets from patients with sepsis
and controls were isolated under identical conditions and
lysed in 100 μl of cell-lysis buffer (Cell Signaling Technol-
ogy, Danvers, MA, USA). Then 30 μg of total protein was
transferred into running buffer, and gel electrophoresis
was performed according to standard protocols in our
laboratory. Protein was blotted onto a PVDF (polyvinyli-
dine difluoride) membrane afterward, and Bcl-xL expres-
sion was detected by using a mouse anti-human antibody
to Bcl-xL (BD Biosciences, Heidelberg, Germany). β-Actin
served as loading control (rabbit anti-human β-Actin; Cell
Signaling Technology). Protein expression was quantified
by band densitometry of a Bcl-xL-to-actin ratio, which
was then compared between groups.
Statistics
Sample-size calculation for the three groups (sepsis, se-
vere sepsis, and control patients) was calculated on the
basis of an estimated 80% difference between groups,
the assumption of a 50% standard deviation, a type I
error (α-error) < 0.05, and a desired power of 80% (type
II error, 20%).
Patient characteristics, clinical scores, and Mmp-Index
values are given as median and interquartile range. Cor-
relations of platelet Mmp-Index and clinical disease
scores (APACHE II, SOFA, SAPS II) were calculated by
using Spearman rank correlation coefficients. Three-group
comparisons were based on Kruskal-Wallis tests as global
test and post hoc Mann–Whitney U tests. Admission
and follow-up Mmp index values were compared with
the Wilcoxon test for paired samples. A P value of < 0.05
was considered statistically significant. Because of theexploratory nature of our analyses, we did not adjust the
test results for multiple testing. Statistical calculations
were performed by using SAS for Unix and Linux, version
9.3 (SAS Institute, Cary, NC, USA).Results
Patient population
In total, 26 patients admitted to our hospital with sepsis,
and 17 control patients were included in the study (Table 1).
Seventeen patients were subclassified as having severe
sepsis including septic shock, whereas nine patients had
nonsevere sepsis and were considered to have no organ
failure, based on a SOFA score of ≤2. The study popu-
lation included 15 male and 11 female patients with a
median age in the severe-sepsis group of 69 years (55
to 78 years), 57 years (42 to 71 years) in the sepsis
group, and 74 years (68 to 79 years) in the control
group. No statistical age difference was found among
the groups. Site of infection in study patients included
pulmonary, urinary, abdominal, soft–tissue, and native
heart-valve infections, as shown in Table 1. In the severe-
sepsis group, median and interquartile range of APACHE
II, SOFA, and SAPS II scores were 23 (15 to 26), 7 (5
to -11) and 53 (40 to 58) and 9 (8 to 13), 0 (0 to 1) and
33 (25 to 35) in the sepsis group (non-severe), respectively.
All disease-severity scores were significantly higher in the
severe sepsis group compared with the nonsevere sepsis
group (APACHE II, P = 0.0009; SOFA, P = 0.0004 and
SAPS II, P = 0.0016). Mortality in the severe-sepsis group
due to septic organ failure was 41% (7 of 17), whereas only
one patient died in the nonsevere sepsis group of a nonin-
fectious cause. Platelet numbers were significantly lower
in the severe-sepsis group on admission compared with



















Figure 2 Comparison of platelet mitochondrial membrane
potential of patients with sepsis, severe sepsis, and control
patients. Box-and-whisker plots illustrate platelet Mmp-Index of patients
with sepsis (nonsevere without organ failure), severe sepsis including
septic shock, and control patients without infection. Lower Mmp-Index
values indicate a loss of mitochondrial membrane potential. Platelet
Mmp-Index was significantly lower in patients with severe sepsis
compared with sepsis without organ failure (P < 0.0006) and controls
(P < 0.0001). No statistical difference was found between patients with
sepsis and controls (P = 0.42). Box margins identify the upper and lower
quartiles; the horizontal line marks the median; and whiskers indicate
minimal and maximal values. Outliers are indicated with a circle.
*Statistically significant difference, P ≤ 0.05.
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(Table 1).
Platelet mitochondrial membrane depolarization
correlates with clinical disease severity
Mean Mmp-Index of triplicate readings of patients admit-
ted with sepsis (n = 26) correlated significantly with the
clinical disease-severity scores APACHE II (r = −0.867;
P < 0.0001), SOFA (r = −0.857; P = 0.0002), and SAPS II
(r = −0.839; P < 0.0001) (Figure 1A-C). A decrease of
Mmp-Index that represents a decrease in mitochondrial
membrane potential was thus paralleled by higher score
numbers, which reflect a more-severe disease status.
Platelet mitochondrial potential is significantly decreased
in patients with severe sepsis
Platelet Mmp-Index is significantly decreased in patients
with severe sepsis, including septic shock, compared with
patients with sepsis without organ failure (nonsevere)
(0.18 (0.12 to 0.25) versus 0.78 (0.51 to 0.85); P < 0.0006)
or control patients (Figure 2). No statistically significant
differences were noted in platelet Mmp-Indices between
the nonsevere sepsis group and control patients (0.78
(0.51 to 0.85) versus 0.89 (0.68 to 1.00); P = 0.42). Among
the sepsis patients, APACHE II, SOFA, and SAPS II scores
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Figure 1 Correlation of platelet mitochondrial membrane potential with APACHE II, SOFA, and SAPS II scores. Dot-blot correlation of the
individual mean platelet Mmp-Index of each patient calculated from triplicate JC-1 FL2 to FL1 fluorescence ratios by flow cytometry and the
clinical disease-severity scores APACHE II (A), SOFA (B), and SAPS II score (C) in 26 patients with sepsis. Lower Mmp-Index values indicate a
loss of mitochondrial membrane potential, whereas higher clinical disease scores indicate more-severe illness. r = statistical correlation coefficient;
P ≤ 0.05 denotes statistically significant correlation of values.
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reference, healthy volunteers (n = 14) showed platelet
Mmp index values of 1.096 (1.049 to 1.398).
Platelet mitochondrial membrane depolarization
correlates with clinical disease outcome
Median platelet Mmp-Index of the group of patients
with severe sepsis who died as a consequence of sepsis
was compared with that of sepsis survivors. On admis-
sion, no significant difference occurred in platelet mito-
chondrial membrane potential between survivors and
nonsurvivors, with a trend to less Mmp-depolarization
in nonsurvivors (P = 0.43) (Figure 3A). Median APACHE II,
SOFA, and SAPS II scores also did not differ between
the groups of survivors and nonsurvivors on admission
(P = 0.14; P = 0.14; and P = 0.18). During the clinical course,
significant recovery of the Mmp-Index was observed in
the group of survivors (0.235 (0.113 to 0.424) to 0.9
(0.713 to 1.017)), whereas persistently low platelet Mmp
values (<0.5 Mmp-Index value) were recorded in the
nonsurvivors group (Figure 3A). Platelet Mmp-Index on
follow-up subsequently showed a significant difference
between the group of sepsis survivors and nonsurvivors
on follow-up (0.269 (0.230 to 0.305) versus 0.9 (0.713
to 1.017)). No significant difference was found in the
follow-up platelet Mmp-Index of survivors and control
patients. Illustration of individual mean Mmp values
for each patient demonstrates the lack of recovery
in nonsurvivors of the severe-sepsis group, which all
remained below 0.5 Mmp-Index, and the recovery of
Mmp-Index values in survivors on follow-up (Figure 3B




















Figure 3 Comparison of platelet mitochondrial membrane potential o
Box-and whisker plots illustrate platelet Mmp-Index of survivors (n = 10) and n
follow-up. Lower Mmp-Index values indicate a loss of mitochondrial membran
between the groups on admission (P = 0.44). No relevant increase was noted
whereas Mmp-Index in survivors recovered to baseline levels of controls. Plate
on follow-up (P = 0.004). Box margins identify the upper and lower quartile; th
maximal values. Outliers are indicated with a circle. *Statistically significant diff
readings of patients in the group of sepsis survivors and nonsurvivors on admFollow-up SOFA scores of nonsurvivors had not im-
proved at 2 weeks’ assessment, whereas SOFA scores in
survivors improved significantly. Admission and follow-up
SOFA scores, corresponding mean Mmp values with
SEM from triplicate readings for each patient, and the
day of the follow-up blood draw in relation to the patient’s
day of discharge or the day a patient died are shown in
Additional file 1.
Bcl-xL expression is decreased in platelets during
severe sepsis
Bcl-xL expression in platelets was demonstrated on ad-
mission in three sepsis patients with an Mmp-Index above
0.8 and nonsevere sepsis compared with four patients with
severe sepsis and low Mmp-Index (Figure 4). Samples of
all these patients were taken on day 1 of admission. Bcl-xL
expression was decreased in platelets during severe sepsis
compared with the sepsis group. Bcl-xL protein expression
was quantified with band densitometry based on actin
loading. Mean Bcl-xL-to-actin ratio of the sepsis group
was set as 1, and severe-sepsis patients were compared
by ratio accordingly. Decrease in Bcl-xL expression in the
severe sepsis group is shown as relative Bcl-xL expression
based on actin.
Discussion
In this study, we demonstrated that platelet mitochondrial
membrane depolarization correlates with disease severity
(APACHE II, SOFA, and SAPS II score) and disease out-
come in patients with sepsis. Mmp-Index was signifi-
cantly decreased in a subgroup of patients with severe

















f survivors and nonsurvivors of the severe-sepsis group. (A)
onsurvivors (n = 7) of the severe-sepsis group on admission and during
e potential. Platelet Mmp-Index did not show significant differences
in platelet Mmp-Index in nonsurvivors during follow-up (Mmp-Index <0.5),
let Mmp-Index was significantly higher in survivors than in nonsurvivors
e horizontal line marks the median; and whiskers indicate minimal and
erence, P≤ 0.05. (B) Individual mean Mmp-Index values from triplicate












































Figure 4 Comparison of Bcl-xL expression in platelets of patients
with sepsis and severe sepsis. Platelet Bcl-xL expression in patients
with sepsis (lanes 1 to 3) and severe sepsis (lanes 4 to 7) on day 1 of
admission was compared with immunoblotting. Bcl-xL expression was
quantified with band-densitometry analysis with the help of a Bcl-xL-
to-actin ratio. Mean Bcl-xL-to-actin ratio for the sepsis group was set as
1, and relative decrease in Bcl-xL expression in the severe-sepsis group
was compared accordingly. Relative Bcl-xL expression between groups
based on actin loading is shown.
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in the severe-sepsis group were significantly reduced com-
pared with the other groups, which implies that the in-
creased apoptotic activity in the septic milieu reflects the
loss of platelets and may explain the prognostic relevance
of thrombocytopenia. Patients classified as sepsis without
organ failure (nonsevere) showed no significant loss of
mitochondrial membrane potential compared with control
patients. This is likely because predicted mortality based
on APACHE II, SOFA, and SAPS II scores in our patients
with nonsevere sepsis was relatively low.
Overall, the link of thrombocytopenia as a predictor of
clinical prognosis in patients in the ICU has been well
established, although investigations on a molecular level
are still rare. Besides a loss of platelets, hemostatic func-
tions of platelets, such as aggregation, are impaired during
sepsis, which also correlates with the severity of infection
[34]. During sepsis, platelets release prothrombotic parti-
cles, which can activate systemic coagulation and lead to
lethal embolic events [35]. Growing evidence suggests that
platelets have the capacity to fight bacterial infections
directly, and that they act as cells of innate immunity
[5,7,8]. We and others have been able to demonstrate
that platelets directly interact with bacteria and release
bactericidal proteins that inhibit bacterial growth [6,36-38].
Bacteria in return release potent exotoxins that driveplatelets into cell death [15]. It is thus not surprising
that platelet numbers decline at a rate that reflects
infectious disease activity and that thrombocytopenia
has prognostic value, as suggested by previous work
[10]. Therefore, it is tempting to speculate that the loss
of platelets is a result of direct bacterial action or the
septic milieu rather than random clearance and con-
sumption of platelets.
Mitochondria are the central target in the intrinsic
apoptotic pathway leading to platelet apoptosis [25], and
mitochondrial damage constitutes an early indicator of
cell death in platelets [33]. Although closely linked to
apoptosis [25,33,39,40], mitochondrial dysfunction is not
an exclusive sign of cell death and can also occur with
microcirculatory distress [41,42]. During clinical or experi-
mental sepsis, mitochondrial dysfunction has also been
observed in heart and skeletal muscle tissue [18,19], as
well as in apoptosis of blood cells such as monocytes [20]
and lymphocytes [43]. Based on experimental data from
our own group and observations by others, we have
reason to believe that mitochondrial dysfunction, platelet
cell death, and thrombocytopenia are not coincidental
in the septic milieu. We have previously shown that live
bacteria (Escherichia coli, Staphylococcus aureus) isolated
from sepsis directly activate a calpain-dependent degrad-
ation pathway that eliminates the anti-apoptotic protein
Bcl-xL [15]. Bcl-xL is critical for platelet survival, and
inhibition or neutralization of Bcl-xL induces platelet
cell death. This process results in platelet mitochondrial
membrane depolarization and programmed cell death of
platelets in vitro. We measured Bcl-xL protein expression
in platelets from patients with sepsis on admission (day 1)
and found decreased expression of Bcl-xL in patients with
severe sepsis who had low Mmp-Index values compared
with patients with nonsevere sepsis (Figure 4) in this
study. We concluded that the septic milieu probably
generates a multitude of factors, including toxins that
damage platelets and reflect the degree of septic activity.
Other groups have described that bacterial factors of
S. aureus induce mitochondrial membrane depolarization
and apoptosis in platelets [44]. Although these observa-
tions support the hypothesis that mitochondrial dysfunc-
tion, apoptosis and thrombocytopenia are physiologically
connected, we cannot prove the link in this complex
in vivo system, but they appear to be reasonable expla-
nations of factors that contribute to the process of sepsis-
induced thrombocytopenia. Undoubtedly, the etiology of
thrombocytopenia in sepsis is multifactorial and includes
microcirculatory and coagulation-associated effects.
A previous study first demonstrated a correlation of
platelet mitochondrial membrane depolarization and clin-
ical disease severity on admission in a diverse group of
medical and surgical ICU patients with SIRS by a different
approach [24]. Before that, Sjövall and colleagues [23]
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respiratory capacity in nonsurvivors compared with survi-
vors of sepsis and demonstrated an association between
mitochondrial dysfunction and clinical outcome in sepsis.
They further detected mitochondrial damage by release of
cytochrome c from mitochondria. However, no correlation
between mitochondrial respiration and standard clinical
assessment scores for illness (APACHE II, SAPS, and
SOFA Score) was found. Most likely, this is explained by a
different approach to assess mitochondrial dysfunction,
which probably differs from the loss of mitochondrial
membrane potential in the apoptotic process.
In this study, we further aimed to investigate whether
the degree of platelet mitochondrial membrane depolar-
ization could also be correlated with disease severity
during the disease course and outcome. We compared
platelet mitochondrial membrane depolarization in a
subgroup of patients with severe sepsis, including septic
shock on admission and during clinical disease course,
and compared Mmp-Index in survivors and nonsurvivors.
On admission, initial Mmp-Index values in the severe-
sepsis group were significantly decreased compared with
controls, but no significant difference between survivors
and nonsurvivors on admission was found (Figure 3A).
Supporting these findings, no difference was noted regard-
ing the clinical disease-severity scores APACHE II, SOFA,
and SAPS II on admission between survivors and nonsur-
vivors in this study. Individual and group analysis of
patients from the sepsis group illustrates that patients
who survived sepsis showed recovery of Mmp-Index on
follow-up, whereas no significant recovery in sepsis
nonsurvivors was observed (Mmp-Index <0.5) (Figure 3A,
B, and Additional file 1). It appears that follow-up Mmp-
reads to identify clinical trends may be equally important
to the absolute Mmp-values. Mmp-Index may prove a
valuable tool to evaluate clinical recovery of the individual
patient in addition to clinical parameters. The data suggest
that markers of platelet apoptosis, such as mitochondrial
membrane potential and Bcl-xL levels, may reflect infec-
tious disease activity and disease severity in sepsis.
Conclusions
Platelet Mmp-Index proved to be a highly reproducible,
easily accessible readout for mitochondrial integrity and
showed good correlation with clinical disease severity
during clinical course, correlated with clinical outcome,
and normalized with recovery. In addition, we detected a
proapoptotic phenotype of platelets based on Bcl-xL levels
in patients with severe sepsis compared with controls.
Further research on larger patient populations will, how-
ever, be necessary to establish markers of platelet apop-
tosis in daily routine. Nonetheless, results from this study
and previous investigations seem to promise that markers
of platelet apoptosis may assist in the assessment ofdisease severity, in risk stratification, and in management
of patients with sepsis in the future.
Key messages
 Platelet mitochondrial membrane depolarization and
decrease of prosurvival proteins correlate with
clinical disease severity in patients with sepsis.
 Platelet mitochondrial membrane potential
correlates with disease outcome, remains low with
unfavorable disease progression, and normalizes
with clinical recovery.
 Markers of platelet apoptosis may aid in the
assessment and risk stratification of patients
with sepsis.
Additional files
Additional file 1: Individual outcome and characteristics of patients
with severe sepsis. The table summarizes the individual SOFA scores on
admission and follow-up, the corresponding individual mean Mmp values
from triplicate readings with SEM for each patient and the day follow-up
blood was drawn in relation to the day of a patient’s discharge (DC) in
survivors, and the day a patient died (D) in nonsurvivors of the severe-sepsis
group. (a) admission, (f) follow-up; DC, day of discharge; D, day of death.
Additional file 2: Illustration of Mmp-Index calculation with flow
cytometry. Flow-cytometry analysis of platelets from a patient with
sepsis (A) and a patient with severe sepsis (B) stained with JC-1 are shown.
Mitochondrial membrane depolarization is characterized by a decrease
in mean red fluorescence (y-axis, FL2) and an increase in mean green
fluorescence (x-axis, FL1) visible in the severe-sepsis sample. Fluorescence
means of red (FL2)-fluorescence and green (FL1)-fluorescence of the platelet
population (circle) are measured, and the ratio FL2 (red) divided by FL1
(green)-fluorescence generates the Mmp-Index. A lower Mmp index thus
represents a loss in mitochondrial membrane potential.
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